Identifying The Relationship Between Biochemical Markers And Healing In Chronic Leg Ulcers Treated With Compression
Funder
National Health and Medical Research Council
Funding Amount
$374,159.00
Summary
Chronic leg ulcers are a significant cause of pain, immobility and decreased quality of life for 1 - 3% of the over 60 years age group. The condition is difficult to heal and commonly becomes a long term problem, costing the Australian health care system over $500 million - year. Additional costs to the community include loss of productivity and social support systems necessary for people with limited mobility. As the number of people aged over 65 years is expected to double in the next few deca ....Chronic leg ulcers are a significant cause of pain, immobility and decreased quality of life for 1 - 3% of the over 60 years age group. The condition is difficult to heal and commonly becomes a long term problem, costing the Australian health care system over $500 million - year. Additional costs to the community include loss of productivity and social support systems necessary for people with limited mobility. As the number of people aged over 65 years is expected to double in the next few decades, this problem will become increasingly significant. Most chronic leg ulcers are caused by venous disease, and compression bandage therapy is the accepted standard treatment. However, there is little information available on the cellular responses associated with compression treatment and how they promote wound healing. The project proposed here will examine the cellular responses to compression and investigate the relationships between these cellular responses and wound healing. Knowledge gained from the study will provide valuable information for improved techniques to promote wound healing, improved ulcer healing rates, informed decisions on wound care treatment, improved qualtiy of life and reduced health care costs.Read moreRead less
Reconciliation strategies for continuous variable quantum key distribution. This project aims to advance a novel key distribution method, called quantum key distribution, which distributes secure keys using the quantum state of optical channels. Key distribution is a foundational part of data security, allowing digital keys to be securely exchanged between two or more parties, before they are used to protect and share information. The expected outcome is new rateless error correction codes desi ....Reconciliation strategies for continuous variable quantum key distribution. This project aims to advance a novel key distribution method, called quantum key distribution, which distributes secure keys using the quantum state of optical channels. Key distribution is a foundational part of data security, allowing digital keys to be securely exchanged between two or more parties, before they are used to protect and share information. The expected outcome is new rateless error correction codes designed specifically to implement quantum key distribution over long distances. Quantum key distribution is beneficial for ultra-secure communications as it avoids the vulnerability to weak random numbers and quantum-computing brute force attacks that currently threated the security of data protected by existing methods. Read moreRead less
Next-generation Glioblastoma Multiforme Therapies Based On Multistage Delivery Nanovectors
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Therapeutic Targeting Of MYCN Oncoprotein Stability In Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$590,206.00
Summary
A high level of MYCN protein is a major indicator of aggressive neuroblastoma (NB) but unfortunately there have been many barriers to the design of targeted therapies. We have identified a protein called PA2G4 which is a cofactor for MYCN in promoting cancer cell growth. We have developed a compound which inhibits PA2G4 and MYCN protein levels and reduces tumour growth. We will examine how PA2G4 cause aggressive tumour characteristics and test new methods to block PA2G4.
Antibiotic Potentiators As An Alternative Therapeutic Option For The Treatment Of Extensively Drug-resistant Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$856,858.00
Summary
Antibiotic mono-therapies are increasingly ineffective for hard-to-treat bacterial infections, forcing clinicians to rely on combinations of antibiotics. Our project has identified compounds that have weak to no antimicrobial potency in their own right, yet when combined with an existing antibiotic they potentiate its activity and restore its ability to treat resistant infections. These antibiotic potentiators are exciting alternatives to current therapies with reduced risk of induced resistance
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
There is an unmet medical need to develop new therapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoints TIGIT and CD96 represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. PD1/PD-L1). While testing these as targets in mice we will also learn more about their ligand CD155 and their expression in human tumors.